OptimizeRx Corp. priced its share at $10 each for a public offering initiated by its shareholder WPP Luxembourg Gamma Three S.À R.L., a unit of WPP PLC.
WPP Luxembourg Gamma Three SÀRL plans to sell its entire holding of 2,103,702 OptimizeRx common shares representing 17.51% of the company as of June 1, according to the most recent S&P Global Market Intelligence data. OptimizeRx will give underwriters a 30-day option to buy as much as an additional 315,555 shares at the public offering price less the underwriting discount and commissions.
OptimizeRx will not receive any proceeds from the offering. However, if the underwriters exercise the option to purchase up to 315,555 additional shares in full, OptimizeRx will receive net proceeds of approximately $2.9 million. OptimizeRx plans to use the proceeds for working capital and other general corporate purposes.
The offering is expected to be complete on or around Dec. 20, subject to customary closing conditions.
William Blair & Co. and B. Riley FBR Inc. are the joint book-running managers for the offering. Roth Capital Partners and Lake Street Capital Markets are the financial advisers for the offering.